Analysts Offer Predictions for CG Oncology FY2029 Earnings

CG Oncology, Inc. (NASDAQ:CGON) – Research analysts at HC Wainwright issued their FY2029 EPS estimates for shares of CG Oncology in a report released on Monday, March 31st. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings per share of $1.34 for the year. HC Wainwright currently has a “Buy” rating and a $75.00 target price on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($1.31) per share.

CGON has been the topic of several other reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $66.00 price target on shares of CG Oncology in a research note on Friday, December 6th. TD Cowen began coverage on shares of CG Oncology in a research note on Tuesday, January 7th. They issued a “buy” rating for the company. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $55.00 price objective on shares of CG Oncology in a research report on Friday, March 7th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $63.88.

CG Oncology Trading Down 15.7 %

CGON stock opened at $18.74 on Wednesday. CG Oncology has a 1-year low of $18.55 and a 1-year high of $46.99. The firm has a market cap of $1.42 billion, a PE ratio of -13.20 and a beta of 1.60. The business’s 50-day moving average price is $27.26 and its two-hundred day moving average price is $31.48.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings results on Tuesday, March 25th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.11). The firm had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.11 million. CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%.

Hedge Funds Weigh In On CG Oncology

A number of institutional investors have recently added to or reduced their stakes in CGON. Decheng Capital LLC grew its position in CG Oncology by 16.3% during the 4th quarter. Decheng Capital LLC now owns 6,371,669 shares of the company’s stock worth $182,739,000 after acquiring an additional 892,859 shares during the last quarter. Vanguard Group Inc. increased its position in CG Oncology by 15.3% during the 4th quarter. Vanguard Group Inc. now owns 5,861,082 shares of the company’s stock valued at $168,096,000 after purchasing an additional 779,730 shares during the period. Braidwell LP increased its position in shares of CG Oncology by 3.5% during the fourth quarter. Braidwell LP now owns 3,283,317 shares of the company’s stock worth $94,166,000 after buying an additional 112,442 shares during the period. Foresite Capital Management VI LLC bought a new position in shares of CG Oncology in the 4th quarter worth about $63,712,000. Finally, Wellington Management Group LLP boosted its holdings in shares of CG Oncology by 274.4% during the 4th quarter. Wellington Management Group LLP now owns 1,910,470 shares of the company’s stock worth $54,792,000 after buying an additional 1,400,251 shares in the last quarter. 26.56% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at CG Oncology

In related news, Director Leonard E. Post sold 1,000 shares of the firm’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $29.66, for a total value of $29,660.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.